CTi Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

1.97USD
6 Jul 2015
Change (% chg)

$-0.01 (-0.51%)
Prev Close
$1.98
Open
$1.93
Day's High
$1.98
Day's Low
$1.92
Volume
221,702
Avg. Vol
657,908
52-wk High
$2.96
52-wk Low
$1.66

CTIC.OQ

Chart for CTIC.OQ

About

CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI... (more)

Overall

Beta: 1.12
Market Cap(Mil.): $356.86
Shares Outstanding(Mil.): 180.23
Dividend: --
Yield (%): --

Financials

  CTIC.OQ Industry Sector
P/E (TTM): -- 454.60 39.81
EPS (TTM): -0.59 -- --
ROI: -210.96 -4.37 16.23
ROE: -439.31 -5.27 17.36
Search Stocks

CTI BioPharma blood cancer drug meets study goal

- CTI BioPharma Corp's experimental blood cancer drug achieved the main goal of a late-stage study, but at least two analysts said the pill would not directly compete with Incyte Corp's treatment.

09 Mar 2015

UPDATE 2-CTI BioPharma blood cancer drug meets study goal

* Shares jump as much as 10.9 pct (Adds analysts comments, background, updates shares)

09 Mar 2015

CTI BioPharma blood cancer drug meets main goal in trial

March 9 - CTI BioPharma Corp said its experimental blood cancer treatment achieved the main goal of a late-stage study.

09 Mar 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ Quantitative Report
$115.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks